Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance
- 22 July 2022
- journal article
- research article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 32 (9) , 1164-1170
Abstract
Objective The benefit of surgery and maintenance treatment with PARP inhibitors (PARPi) has been clearly demonstrated in ovarian cancer. Also, the efficacy and safety of stereotactic body radiotherapy has been shown in patients with metastatic, persistent, and recurrent disease. The aim of this study is to evaluate the management of oligometastatic progression during PARPi maintenance treatment. Methods This is an observational, retrospective, single-arm study conducted from June 2017 to December 2020 in patients with recurrent ovarian cancer with oligometastatic progression under PARPi maintenance treatment and receiving surgery or stereotactic body radiotherapy for such recurrence. PARPi treatment was continued until further progression of the disease. The primary objective of the study was the median prolongation of the treatment-free interval-p (without platinum) after local treatment. Results A total of 186 patients with ovarian cancer were treated with PARPi at recurrence. Of these, 30 (16%) developed oligometastatic progression. The median age was 49.5 years (range 35–73). Olaparib, niraparib and rucaparib were administered to 33%, 60%, and 7% of patients, respectively. The median prolongation of the treatment-free interval-p of patients treated with surgery or stereotactic body radiotherapy was 6 and 10 months, respectively (p=0.53). The median treatment-free interval-p of patients treated with surgery or stereotactic body radiotherapy at the time of oligometastatic progression was 32 and 29 months, respectively (p=0.44). At the time of this publication, 50% of patients are still on treatment with PARPi following progression. Conclusions Patients with recurrent ovarian cancer who have oligometastic progression during PARPi maintenance may continue to benefit from PARPi if combined with local treatment.Keywords
This publication has 37 references indexed in Scilit:
- Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in TurkeyAsian Pacific Journal of Cancer Prevention, 2016
- Long-term Benefit of Tumor Volume-DirectedInternational Journal of Gynecological Cancer, 2016
- Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapyGynecologic Oncology, 2016
- Involved-field radiation therapy for locoregionally recurrent ovarian cancerGynecologic Oncology, 2013
- Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapyJournal of Radiation Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated seriesGynecologic Oncology, 2010
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Tertiary cytoreductive surgery in recurrent ovarian cancer: Selection criteria and survival outcomeGynecologic Oncology, 2007
- Selective Irradiation for the Treatment of Recurrent Ovarian Carcinoma Involving the Vagina or RectumGynecologic Oncology, 2001